MX2024001322A - Derivados de piridina sustituida como inhibidores de sarm1. - Google Patents
Derivados de piridina sustituida como inhibidores de sarm1.Info
- Publication number
- MX2024001322A MX2024001322A MX2024001322A MX2024001322A MX2024001322A MX 2024001322 A MX2024001322 A MX 2024001322A MX 2024001322 A MX2024001322 A MX 2024001322A MX 2024001322 A MX2024001322 A MX 2024001322A MX 2024001322 A MX2024001322 A MX 2024001322A
- Authority
- MX
- Mexico
- Prior art keywords
- sarm1
- pyridine derivatives
- substituted pyridine
- nad
- inhibition
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 abstract 3
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 abstract 3
- 230000007850 degeneration Effects 0.000 abstract 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 abstract 2
- 230000003376 axonal effect Effects 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 102000002250 NAD+ Nucleosidase Human genes 0.000 abstract 1
- 108010000193 NAD+ Nucleosidase Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000003050 axon Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226557P | 2021-07-28 | 2021-07-28 | |
| US202263305103P | 2022-01-31 | 2022-01-31 | |
| US202263368034P | 2022-07-08 | 2022-07-08 | |
| PCT/US2022/038577 WO2023009663A1 (en) | 2021-07-28 | 2022-07-27 | Substituted pyridine derivatives as sarm1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001322A true MX2024001322A (es) | 2024-04-30 |
Family
ID=85087993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001322A MX2024001322A (es) | 2021-07-28 | 2022-07-27 | Derivados de piridina sustituida como inhibidores de sarm1. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11629136B1 (enExample) |
| EP (1) | EP4376840A4 (enExample) |
| JP (1) | JP2024528036A (enExample) |
| KR (1) | KR20240041987A (enExample) |
| AU (1) | AU2022320699A1 (enExample) |
| CA (1) | CA3226869A1 (enExample) |
| CL (1) | CL2024000239A1 (enExample) |
| CO (1) | CO2024001716A2 (enExample) |
| IL (1) | IL310403A (enExample) |
| MX (1) | MX2024001322A (enExample) |
| TW (1) | TW202313009A (enExample) |
| WO (1) | WO2023009663A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12404265B2 (en) | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| CN116438171A (zh) | 2020-09-16 | 2023-07-14 | 努拉生物公司 | 作为sarm1抑制剂的取代的吡啶衍生物 |
| EP4304586A4 (en) | 2021-03-10 | 2025-04-02 | Jnana Therapeutics Inc. | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION |
| EP4376840A4 (en) * | 2021-07-28 | 2025-05-21 | Nura Bio, Inc. | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS |
| CN113655155A (zh) * | 2021-07-28 | 2021-11-16 | 任贤金 | 一种测定sph3127有关物质的方法 |
| EP4562001A1 (en) * | 2022-07-27 | 2025-06-04 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| CN120424050A (zh) * | 2024-02-05 | 2025-08-05 | 科辉智药(深圳)新药研究中心有限公司 | 作为sarm1酶活性抑制剂的吡啶类化合物及其应用 |
| WO2025179205A1 (en) * | 2024-02-23 | 2025-08-28 | Nura Bio, Inc. | Methods for the treatment of neurological disorders |
| WO2026080488A1 (en) | 2024-10-09 | 2026-04-16 | Genentech, Inc. | Heterocyclic compounds for the treatment of neurodegenerative diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9781098A (en) * | 1997-10-02 | 1999-04-27 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| CA2460345A1 (en) * | 2001-09-13 | 2003-03-20 | Synta Pharmaceuticals Corp. | 2-aroylimidazole compounds for treating cancer |
| DE102004009933A1 (de) | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Verwendung von Thiadiazolharnstoffderivaten |
| WO2005105780A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| PE20060426A1 (es) * | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| US8236824B2 (en) | 2007-10-09 | 2012-08-07 | MERCK Patent Gesellschaft mit beschränkter Haftung | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators |
| WO2009114552A1 (en) | 2008-03-10 | 2009-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| US8785468B2 (en) | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| WO2012049161A1 (en) | 2010-10-13 | 2012-04-19 | Glaxo Group Limited | 3 -amino- pyrazole derivatives useful against tuberculosis |
| WO2012050141A1 (ja) | 2010-10-14 | 2012-04-19 | 住友化学株式会社 | ヘテロ芳香環化合物およびその有害生物防除用途 |
| JP6282721B2 (ja) | 2013-03-14 | 2018-02-21 | ダート・ニューロサイエンス・（ケイマン）・リミテッド | Ｐｄｅ４阻害剤としての置換ピリジン及びピラジン化合物 |
| AR096393A1 (es) | 2013-05-23 | 2015-12-30 | Bayer Cropscience Ag | Compuestos heterocíclicos pesticidas |
| WO2015140130A1 (en) | 2014-03-17 | 2015-09-24 | Remynd Nv | Oxadiazole compounds |
| WO2015175704A1 (en) * | 2014-05-14 | 2015-11-19 | The Regents Of The University Of California | Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria |
| CA2955872A1 (en) | 2014-07-24 | 2016-01-28 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| JP2018515623A (ja) | 2015-05-18 | 2018-06-14 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | キナーゼ阻害剤としての複素環式化合物 |
| US20170355708A1 (en) | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| EP3541806A4 (en) | 2016-11-21 | 2020-07-01 | Translational Drug Development, LLC | HETEROCYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS |
| CA3108669A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| KR20210143783A (ko) * | 2019-02-28 | 2021-11-29 | 케자르 라이프 사이언스 | 단백질 분비 저해제로서 티아졸 유도체 |
| JP7289375B2 (ja) * | 2019-06-06 | 2023-06-09 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| US12595252B2 (en) | 2019-06-14 | 2026-04-07 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| CA3150878A1 (en) * | 2019-09-12 | 2021-03-18 | Jonathan Bentley | Inhibitors of sarm1 |
| WO2021142006A1 (en) * | 2020-01-07 | 2021-07-15 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| US12435084B2 (en) | 2020-04-09 | 2025-10-07 | Eli Lilly And Company | Indazole derivatives as inhibitors of SARM1 |
| US12404265B2 (en) | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| TWI904906B (zh) | 2020-08-24 | 2025-11-11 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| CN116438171A (zh) | 2020-09-16 | 2023-07-14 | 努拉生物公司 | 作为sarm1抑制剂的取代的吡啶衍生物 |
| EP4376840A4 (en) | 2021-07-28 | 2025-05-21 | Nura Bio, Inc. | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS |
| EP4562001A1 (en) | 2022-07-27 | 2025-06-04 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
-
2022
- 2022-07-27 EP EP22850281.1A patent/EP4376840A4/en active Pending
- 2022-07-27 JP JP2024505223A patent/JP2024528036A/ja active Pending
- 2022-07-27 IL IL310403A patent/IL310403A/en unknown
- 2022-07-27 CA CA3226869A patent/CA3226869A1/en active Pending
- 2022-07-27 US US17/875,301 patent/US11629136B1/en active Active
- 2022-07-27 WO PCT/US2022/038577 patent/WO2023009663A1/en not_active Ceased
- 2022-07-27 MX MX2024001322A patent/MX2024001322A/es unknown
- 2022-07-27 KR KR1020247006685A patent/KR20240041987A/ko active Pending
- 2022-07-27 TW TW111128145A patent/TW202313009A/zh unknown
- 2022-07-27 AU AU2022320699A patent/AU2022320699A1/en active Pending
-
2023
- 2023-03-03 US US18/178,325 patent/US12110285B2/en active Active
-
2024
- 2024-01-26 CL CL2024000239A patent/CL2024000239A1/es unknown
- 2024-02-19 CO CONC2024/0001716A patent/CO2024001716A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11629136B1 (en) | 2023-04-18 |
| JP2024528036A (ja) | 2024-07-26 |
| KR20240041987A (ko) | 2024-04-01 |
| US20230105696A1 (en) | 2023-04-06 |
| US12110285B2 (en) | 2024-10-08 |
| WO2023009663A1 (en) | 2023-02-02 |
| CL2024000239A1 (es) | 2024-06-07 |
| CO2024001716A2 (es) | 2024-03-07 |
| US20230286941A1 (en) | 2023-09-14 |
| EP4376840A1 (en) | 2024-06-05 |
| IL310403A (en) | 2024-03-01 |
| CA3226869A1 (en) | 2023-02-02 |
| TW202313009A (zh) | 2023-04-01 |
| EP4376840A4 (en) | 2025-05-21 |
| AU2022320699A1 (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001322A (es) | Derivados de piridina sustituida como inhibidores de sarm1. | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| MY206478A (en) | Inhibitors of sarm1 | |
| MX2024004444A (es) | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). | |
| ZA202301801B (en) | Inhibitors of sarm1 | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| MX2025012306A (es) | Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano | |
| MX2024003612A (es) | Composiciones de oligonucleotidos y metodos de estas. | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| PH12021552555A1 (en) | Dihydroorotate dehydrogenase inhibitors | |
| MX2021009521A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
| MXPA05007689A (es) | Tratamiento de enfermedades con agonistas completos del receptor alfa-7 de nach. | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| WO2021195066A3 (en) | Kcnt1 inhibitors and methods of use | |
| PH12021551446A1 (en) | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 | |
| MX2024004993A (es) | Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| MX2022010625A (es) | Inhibidores de kcnt1 y metodos de uso. | |
| WO2022140547A3 (en) | Kcnt1 inhibitors and methods of use | |
| WO2023055885A3 (en) | Ezh2 inhibition in pancreatic cancer | |
| MX2021012417A (es) | Anillos de piridina que contienen derivados como inhibidores de malt1. | |
| MX2025011864A (es) | Potenciadores de kcc2 y usos de estos | |
| MX2022011646A (es) | Celulas t v delta1+ para el tratamiento de neoplasias mieloides. | |
| MX2025014420A (es) | Inhibidores de cinasa janus canina y usos de los mismos | |
| MX2022002470A (es) | Inhibidores de dihidroorotato deshidrogenasa sustituidos con urea. | |
| MX2025006420A (es) | Inhibidores de adar1 y métodos de uso de estos |